

Zentrum für Kardiovaskuläre
Genetik und Gendiagnostik

Genetic Assessment in Patients with a Large Aorta

PD Dr. Gabor Matyas

Center for Cardiovascular Genetics and Gene Diagnostics, Schlieren ZH

matyas@genetikzentrum.ch

www.genetikzentrum.ch

Genetic Assessment in Patients with a Large Aorta



Why?
When?
Where?

Genetic Assessment in Patients with a Large Aorta




Why?

Why is important the genetic assessment of patients with large aorta?

Why is important to know which gene is mutated?


Why is important to know the diseases-causing mutation?

Why is Genetic Testing Important?



- To make an accurate diagnosis
- To know the genetic background of the aortic disease: Requirement for targeted management and therapy
- To clarify whether the aortic disease is inherited: clarification on unclear phenotype, presymptomatic genetic testing, prenatal diagnosis, and preimplantation genetic diagnosis (in Switzerland only by using polar bodies => applicable for affected females)
- For mutation databases and special studies (genotype-phenotype studies, understanding of the molecular pathogenesis and phenotypic variability of aortic diseases)

Hereditary Aortic Diseases



But several other genes have been associated with hereditary aneurysm conditions in humans and/or in mouse models, such as *ACVRL1*, *COL1A1*, *COL1A2*, *COL4A1*, *COL4A5*, *EFEMP2*, *ELN*, *ENG*, *FLNA*, *GAA*, *GLA*, *GJA1*, *JAG1*, *KLF15*, *KLF2*, *LOX*, *MED12*, *NF1*, *NOS3*, *NOTCH1*, *NPHP3*, *PKD1*, *PKD2*, *PLOD1*, *PLOD3*, *PTPN11*, *S100A12*, and *TSC2*

Loeys-Dietz aortic aneurysm syndrome (LDS) characterized by arterial aneurysms, tortuous arteries, Marfanoid habitus, and craniofacial features;


Familial thoracic aortic aneurysms and dissections (TAAD), in which the phenotype is essentially restricted to the aorta;

Vascular type of Ehlers–Danlos syndrome (EDS IV), characterized by arterial rupture, thin/translucent skin, extensive bruising, characteristic facial appearance, and intestinal/uterine rupture;

Aneurysms-osteoarthritis syndrome (AOS), a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis;

Autosomal recessive **arterial tortuosity syndrome (ATS)** characterized by elongation, tortuosity, kink, and aneurysm formation in the major arteries.

Hereditary Aortic Diseases



But several other genes have been associated with hereditary aneurysm conditions in humans and/or in mouse models, such as *ACVRL1*, *COL1A1*, *COL1A2*, *COL4A1*, *COL4A5*, *EFEMP2*, *ELN*, *ENG*, *FLNA*, *GAA*, *GLA*, *GJA1*, *JAG1*, *KLF15*, *KLF2*, *LOX*, *MED12*, *NF1*, *NOS3*, *NOTCH1*, *NPHP3*, *PKD1*, *PKD2*, *PLOD1*, *PLOD3*, *PTPN11*, *S100A12*, and *TSC2*

In the presence of aortic aneurysm/dissection and absence of other discriminating clinical features, only genetic testing can distinguish aortic diseases, allowing accurate diagnosis.

Why is Genetic Testing Important?




- To make an accurate diagnosis
- To know the genetic background of the aortic disease:
Requirement for **targeted management and therapy**
- To clarify whether the aortic disease is inherited:
clarification on unclear phenotype, presymptomatic
genetic testing, prenatal diagnosis, and preimplantation
genetic diagnosis (in Switzerland only by using polar
bodies => applicable for affected females)
- For mutation databases and special studies (genotype-
phenotype studies, understanding of the molecular
pathogenesis and phenotypic variability of aortic diseases)

Targeted Management




- Individuals with an aortic disease-causing mutation require regular surveillance and **appropriate mode of life**
- Individuals with a *TGFBR1/2* mutation (TGF β receptor defects) tend to rupture at younger age and smaller aortic diameters, requiring more frequent imaging
- Mutations in the genes *COL3A1*, *MYLK*, and *SMAD3* can result in aortic dissection and/or rupture with little to no aortic enlargement
- Individuals with a *COL3A1* mutation require special care (fragile tissue, spontaneous arterial rupture)

Targeted Therapy



Matt et al. 2008, J Thorac Cardiovasc Surg 135:389-94

Postnatal treatment with losartan, propranolol, or placebo in mice with *Fbn1* mutation (p.C1039G). Verhoeff–van Gieson staining.



Whereas patients with mutations leading to increased level of TGF-beta could benefit from a treatment with **losartan**, patients with mutations leading to increased proteolysis in the aortic wall may respond to a drug therapy with **doxycycline** (inhibitor of matrix metalloproteases).

Why is Genetic Testing Important?



- To make an accurate diagnosis
- To know the genetic background of the aortic disease:
Requirement for targeted management and therapy
- To clarify whether the aortic disease is inherited:
clarification on unclear phenotype, presymptomatic
genetic testing, prenatal diagnosis, and preimplantation
genetic diagnosis (in Switzerland only by using polar
bodies => applicable for affected females)
- For mutation databases and special studies (genotype-
phenotype studies, understanding of the molecular
pathogenesis and phenotypic variability of aortic diseases)

Why is Genetic Testing Important?




- To make an accurate diagnosis
- To know the genetic background of the aortic disease:
Requirement for targeted management and therapy
- To clarify whether the aortic disease is inherited:
clarification on unclear phenotype, presymptomatic
genetic testing, prenatal diagnosis, and preimplantation
genetic diagnosis (in Switzerland only by using polar
bodies => applicable for affected females)
- For mutation databases and special studies (genotype-
phenotype studies, understanding of the molecular
pathogenesis and phenotypic variability of aortic diseases)

Genetic Assessment in Patients with a Large Aorta



Why?
When?
Where?

1. Aortic Aneurysm at Young Age



Jondeau & Boileau, Curr Atheroscler Rep, 2012 Mar 14 [Epub ahead of print]

Different groups of patients with thoracic aortic aneurysm according to their age at surgery. BAV—bicuspid aortic valve

2. Clinical Signs Suggesting Aortic Disease





Table 2 Comparison of the main clinical features in aneurysm syndromes

Features	AOS (%) N = 27	LDS type I ¹¹ (%) N = 40	LDS type II ¹¹ (%) N = 12	MFS ¹⁹ (%) N = 1,013
Cardiovascular				
• Aortic root aneurysm/ dissection	58	98	100	77
Aneurysms of other vessels	41	52	73	7
• Arterial tortuosity	53	84	67	–
Mitral valve abnormalities	59	29 ^b	–	54
Congenital heart disease	9	35	–	–
Other heart diseases	32 ^a	–	–	–
Skeletal				
• Pectus deformity	16	68	–	59
• Scoliosis	43	50	–	53
• Joint laxity (Beighton score ≥5)	19	68	100	63
Joints				
• Osteoarthritis ≥ 1 joint	100	–	–	–
Intervertebral disc degeneration	90	–	–	–
OCD or meniscal abnormalities	72	–	–	–
Craniofacial				
• Hypertelorism	37	90	0	–
• Abnormal palate/uvula	58	90	25	–
Craniosynostosis	0	48	0	–
Skin/integument				
• Velvety skin	67	28	82	–
Herniae	50	–	36	10
Other				
• Ectopia lentis	0	0	–	54


^aLeft ventricular hypertrophy and atrial fibrillation. ^bBased on 16 cases⁵. –, not reported in referred articles.

3. Aortic Aneurysm in Family Members



	GTC	GGG	GTG	TGC	TGG	TCG
Human (<i>H. sapiens</i>)	GTC	GGG	GTG	TGC	TGG	TCG
Chimp (<i>P. troglodytes</i>)
Dog (<i>C. familiaris</i>)T
Mouse (<i>M. musculus</i>)C
Rat (<i>R. norvegicus</i>)C
Chicken (<i>G. gallus</i>)	..G	..T	..T	..T	..T	..T
Fugu (<i>T. rubripes</i>)AC
Zebrafish (<i>D. rerio</i>)	..GTT


Matyas et al. 2006, Hum Mutat 27:760-769



Genetic Assessment in Patients with a Large Aorta



Why?
When?
Where?



Willkommen

Das Zentrum für Kardiovaskuläre Genetik und Gendiagnostik ist schweizweit das erste und einzige Zentrum, welches auf die molekulare Gendiagnostik und die Erforschung genetisch bedingter Aortenkrankheiten und deren klinische Konsequenzen, wie Aneurysmen und Dissektionen, spezialisiert ist.

Unsere Kompetenz beruht auf langjähriger Erfahrung auf diesem Gebiet:

- 1999 – 2002 Kinderspital Zürich (UZH)
- 2003 – 2010 Institut für Medizinische Genetik (UZH)
- 2010 – 2011 Institut für Medizinische Molekulargenetik (UZH)
- ab 2012 Zentrum für Kardiovaskuläre Genetik und Gendiagnostik

Unsere Stärke liegt darin, dass die Haupttätigkeitsbereiche des Zentrums – Forschung, Lehre, Gendiagnostik und interdisziplinäre Beratung – ineinandergreifen, zusammenarbeiten und sich dadurch gegenseitig unterstützen und vorwärtsbringen.

Das Leitbild des Zentrums finden Sie » [hier](#)  (pdf) — Weitere Information »  (pdf)

Unsere Meinung zu Internet-Genests »  (pdf) — Personalisierte Medizin »  (pdf)

Genetikzentrum für Aortenkrankheiten

Das Zentrum für Kardiovaskuläre Genetik und Gendiagnostik arbeitet mit renommierten Institutionen und führenden Klinikern und Forschern in der Schweiz und im Ausland zusammen. » [Mehr](#)

Aortenkrankheiten – seltene Krankheiten



Aortenkrankheiten, wie beispielsweise das Marfan Syndrom, gehören zu den seltenen Krankheiten. » [Mehr](#)

Anschrift

Zentrum für Kardiovaskuläre Genetik und Gendiagnostik
Wagistrasse 25
CH-8952 Schlieren ZH

Direkt zu

- » [Anmeldeformular](#)
- » [Gendiagnostikangebote](#)
- » [Polkörperdiagnostik](#)
- » [Sprechstundenvereinbarung](#)
- » [Forschungsschwerpunkte](#)
- » [Publikationen](#)
- » [Masterarbeitangebote](#)



Angebot

Angebot

Anmeldeformular

Untersuchungsmaterial

Polkörperdiagnostik

Links & Downloads

Wir bieten molekulargenetische DNA-Untersuchungen bei folgenden Krankheiten und Genen an:


• Acromicric & Geleophysic Dysplasias (» AD & GD)	<i>FBN1</i>
• Aneurysma Osteoarthrose Syndrom (» AOS)	<i>SMAD3</i>
• Arterientortuositätssyndrom (» ATS)	<i>SLC2A10</i>
• Barth Syndrom (» BTHS)	<i>TAZ</i>
• Birt-Hogg-Dubé Syndrom (» BHD) / Pneumothorax	<i>FLCN</i>
• Ehlers-Danlos Syndrom Typ IV (» EDS IV)	<i>COL3A1</i>
• Hirn-Aneurysmata (» IA)	<i>COL3A1, TGFBR3</i>
• Kongenitale kontrakturale Arachnodaktylie (» CCA)	<i>FBN2</i>
• Linsenektopie (» EL)	<i>FBN1</i>
• Loeys-Dietz-Aortenaneurysma Syndrom (» LDS)	<i>TGFBR1, TGFBR2</i>
• Marfan Syndrom (» MFS) » mehr	<i>FBN1</i>
• Mitralklappenprolaps (» MVP)	<i>FBN1</i>
• Morbus Fabry (in Zusammenarbeit mit » IMD und » KISPI) » mehr	<i>GLA</i>
• Noonan Syndrom (» NS1)	<i>PTPN11</i>
• Progeroid Syndrom ähnliche Lipodystrophie » mehr	<i>FBN1</i>
• Shprintzen-Goldberg Syndrom (» SGS)	<i>FBN1, TGFBR1, TGFBR2</i>
• Stiff-Skin Syndrom (» SSS)	<i>FBN1</i>
• Thorakale Aneurysmen und Dissektionen der Aorta (» TAAD)	<i>FBN1, TGFBR1, TGFBR2, ACTA2, MYH11, MYLK, EFEMP2</i>
• Thorakales Aortenaneurysma mit Ductus arteriosus persistens (» PDA)	<i>MYH11</i>
• Triple-X Syndrom (» 47,XXX)	<i>47,XXX</i>
• Turner Syndrom (» TS)	<i>45,X</i>
• XXY Syndrom (» Klinefelter Syndrom) / XYY Syndrom (» 47,XXY)	<i>47,XXY / 47,XYY</i>
• Weill-Marchesani Syndrom, autosomal-dominant (» WMS)	<i>FBN1</i>

Weitere Gendiagnostikangebote:

- Kopplungsuntersuchungen bei Familien mit einer segregierenden Krankheit
- Polkörperdiagnostik (PKD; nur nach Voranmeldung) » **mehr**
- Nach Rücksprache können wir DNA-Untersuchungen auch für weitere monogene Krankheiten anbieten

Stiftung für Menschen mit seltenen Krankheiten

www.stiftung-seltene-krankheiten.ch






Zentrum für Kardiovaskuläre Genetik und Gendiagnostik


Leiter: PD Dr. Gabor Matyas, FAMH Medizinische Genetik

Stellvertreterin: Caroline Henggeler, FAMH Medizinische Genetik

www.genetikzentrum.ch



Acknowledgement




Center for Cardiovascular Genetics and Gene Diagnostics

Nicole Amstutz, Eliane Arnold, Caroline Henggeler, Martina Fischler, Nicole Mahlberg, Janine Meienberg, Doina Muncaciu, Arash Najafi, Tony Nguyen, Regina Perez, Philippe Reuge

Funding

Stiftung für Menschen mit seltenen Krankheiten, COFRA Foundation, Gottfried & Julia Bangerter-Rhyner-Stiftung, Schweizerischer Nationalfonds, Schweizerische Herzstiftung, Forschungskredit der Universität Zürich, Telethon



Zentrum für Kardiovaskuläre Genetik und Gendiagnostik

Thank you for your attention!

Our opinion about internet gene tests:

http://www.genetikzentrum.ch/view/userfiles/files/Sonntag_Nr4_Interview.pdf

«Die Zukunft der Medizin liegt in der Genetik:

Es ist immer offensichtlicher, dass sich die Medizin in Prävention,
Diagnose und Therapie an der Genetik orientieren muss.»

(Prof. Dr. med. Jan Murken, Klinikum der Universität München)